Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

Inclusion Criteria:

• Participants must sign and date the consent document.

• Participants diagnosed with moderate to severe Atopic dermatitis (AtD) who havecompleted the qualifying Phase 2 parent study (NCT05999799) of GlaxoSmithKline (GSK's) AtD and, in their opinion, may benefit from GSK1070806.

• Be intentional and able to visit the doctor at the clinic by appointment and followall procedures related to research studies and questionnaires (able to read andunderstand Patient-reported outcomes (PRO) questionnaires and be able to useelectronic devices).

• The use of contraceptive methods for females should be consistent with localregulations on contraceptive methods of participants participating in clinicalresearch programs.

• Female participants are eligible to participate in the research program if they arenot pregnant or breastfeeding and meet one of the following conditions:

• It is Woman of nonchildbearing potential (WONCBP).

• It is Woman of childbearing potential (WOCBP) and uses a highly effectivecontraceptive method that has a failure rate less than (<) 1 percent (%) during thetrial dose period and for at least 16 weeks after the last dose of the researchdrug. We should assess the likelihood of contraceptive failure (e.g.,non-cooperation, early contraception) associated with the first dose of the drug.

• WOCBP must obtain a negative result in a highly sensitive pregnancy test (by urineor serum test, as prescribed by local regulations) before receiving the first doseof the research drug.

• If the urine test is positive, or the negative result cannot be confirmed (i.e., theresult is unclear), a pregnancy test by serum test is required. In such cases, Ifthe serum is tested, the test result is positive. Participants must be excluded fromthe research project.

• Additional requirements for testing pregnancy during and after exposure to the drug.

• The researcher is responsible for examining medical history, menstrual cyclehistory, and sexual activity in the near term. To reduce the risk of screeningpregnant women who may not be detected at the beginning of pregnancy.

Exclusion Criteria:

• Permanent discontinuation of the study drug at any time during GSK's qualifyingPhase 2 AtD (NCT05999799) or a medical condition that would hinder GSK'sparticipation in the Phase 2 219538 (NCT05999799) AtD research project.

• Participants who, during GSK's qualifying Phase 2 (NCT05999799) AtD researchproject, developed adverse event (AE) or Serious adverse event (SAE) based onlaboratory parameters, physical examination, vital signs, Electrocardiogram (ECG),medical history, etc. Medical history, in the opinion of the researchers, suggeststhat if Investigational medicinal product (IMP) is continued, it may causeunnecessary risk to the participants.

• Topical medications for AtD within 1 week prior to your appointment at Day 1, suchas: Topical calcineurin inhibitors (TCI)/ Topical corticosteroids (TCS),Phosphodiesterase-4 (PDE-4) and Janus activation kinase inhibitors (JAKi) forexternal use.

• Topical corticosteroids (TCS) (such as hydrocortisone, betamethasone)

• Topical calcineurin inhibitors (TCI) (such as tacrolimus, pimecrolimus)

• Phosphodiesterase-4 (PDE4) inhibitor for external use (e.g., crisaborole)

• JAKi for external use (e.g. ruxolitinib)

• Medications for topical use, or other herbal/traditional medicines that may affectthe AtD that the participants are in.

• Participant who received systemic therapy, which is considered contraindicated,including systemic therapy used as a rescue medication for AtD, from the screeningfor GSK's Phase 2 AtD 219538 research project until the LTE protocol began, wereunable to participate in the research project.

• Chronic uncontrolled diseases that may require immediate oral corticosteroids, suchas severe uncontrolled asthma (defined as having an Asthma control questionnaire (ACQ)-5 score greater than or equal to (>=) of 1.5 or a history of asthmaexacerbations. >= 2 times within the last 12 months, requiring systemiccorticosteroid [oral and/or intravenous medication] or requiring a >-24-hourhospital stay)

• Experience participating in previous/current clinical research projects.

• The participants have participated in any other clinical research studies. This isin addition to GSK's Phase 2 219538 (NCT05999799) research project.